Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Clarity Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Health & Biotech
Check Up: Australian biotech sector continues to be a magnet for US investors
Health & Biotech
ASX Health Stocks: Althea says its cannabis beverage could generate $5m of sales in Canada
Health & Biotech
ASX Health Stocks: Firebrick achieves primary endpoint in Phase 2; Memphasys surges 20pc on Japan deal
News
ASX Health Stocks: Living Cells Tech files a patent for cannabis-based dementia drug
Health & Biotech
ASX Health Stocks: US FDA happy to review anal fissure drug; gives green light to Clarity’s Phase 3 trial
News
Market Highlights: Battery stocks on watch as Tesla surges; RBA to hand down rates decision today
Health & Biotech
ASX Health Stocks: Ramsay Healthcare up 7pc as its looks to sell joint Asian Venture
Health & Biotech
ASX Health Stocks: Clarity to expand Phase 3 trial sites; CSL downgrades profit on FX headwinds
Experts
MoneyTalks: Broker Wilsons reckons this youth apparel retailer is attractive and undervalued
Health & Biotech
ASX Health Stocks: Patrys, Immutep jump after reports show drugs well tolerated
News
Closing Bell: ASX slides 0.40%, gold tanks, but rare earths stocks have a exceptional day
Health & Biotech
ASX Health Stocks: CleanSpace and Sonic Healthcare leap double digits today on US, trial wins
Health & Biotech
ASX Health Stocks: Clarity Pharma shows effectiveness in diagnosing prostate lesions in Phase 1 trial
News
ASX Large Caps: Local shares breeze through the first week of 2023, up by more than 1pc
Health & Biotech
ASX Health Stocks: Clarity reveals Phase 1 success; Starpharma and Oncosil head for Asia
Health & Biotech